Your browser doesn't support javascript.
loading
COPD Exacerbations Before and During COVID-19 in France, Germany, Italy, the UK and the US.
Martinez, Fernando J; Papi, Alberto; Welte, Tobias; Singh, Dave; Galkin, Dmitry V; Guasconi, Alessandro; Pirondi, Stefania; Georges, George; Imperato, Joseph; Hermans, Ruben.
Afiliación
  • Martinez FJ; Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.
  • Papi A; Research Center on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
  • Welte T; Pneumonology and Infectiology, Member of the German Center of Lung Research, Hannover Medical School, Hannover, Germany.
  • Singh D; Biomedical Research in End Stage and Obstructive Lung Disease, German Center for Lung Research, Hannover Medical School, Hannover, Germany.
  • Galkin DV; Medicines Evaluations Unit, University of Manchester, Manchester University Foundation Hospitals Trust, Manchester, UK.
  • Guasconi A; Global Clinical Development, Chiesi USA, Cary, NC, USA.
  • Pirondi S; Global Clinical Development, Chiesi Farmaceutici, S.p.A, Parma, Italy.
  • Georges G; Global Clinical Development, Chiesi Farmaceutici, S.p.A, Parma, Italy.
  • Imperato J; Global Clinical Development, Chiesi Farmaceutici, S.p.A, Parma, Italy.
  • Hermans R; Medical Affairs, IQVIA Inc, New York, NY, USA.
Int J Chron Obstruct Pulmon Dis ; 19: 1433-1445, 2024.
Article en En | MEDLINE | ID: mdl-38948907
ABSTRACT

Background:

Exacerbations of chronic obstructive pulmonary disease (COPD) were reported less frequently during the COVID-19 pandemic. We report real-world data on COPD exacerbation rates before and during this pandemic.

Methods:

Exacerbation patterns were analysed using electronic medical records or claims data of patients with COPD before (2017-2019) and during the COVID-19 pandemic (2020 through early 2022) in France, Germany, Italy, the United Kingdom and the United States. Data from each country were analysed separately. The proportions of patients with COPD receiving maintenance treatment were also estimated.

Results:

The proportion of patients with exacerbations fell 45-78% across five countries in 2020 versus 2019. Exacerbation rates in most countries were reduced by >50% in 2020 compared with 2019. The proportions of patients with an exacerbation increased in most countries in 2021. Across each country, seasonal exacerbation increases seen during autumn and winter in pre-pandemic years were absent during the first year of the pandemic. The percentage of patients filling COPD prescriptions across each country increased by 4.53-22.13% in 2019 to 9.94-34.17% in 2021.

Conclusion:

Early, steep declines in exacerbation rates occurred in 2020 versus 2019 across all five countries and were accompanied by a loss of the seasonal pattern of exacerbation.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Progresión de la Enfermedad / Enfermedad Pulmonar Obstructiva Crónica / COVID-19 Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte / Europa Idioma: En Revista: Int J Chron Obstruct Pulmon Dis Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Progresión de la Enfermedad / Enfermedad Pulmonar Obstructiva Crónica / COVID-19 Límite: Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte / Europa Idioma: En Revista: Int J Chron Obstruct Pulmon Dis Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos